Zymeworks Inc. (NYSE:ZYME) Director Purchases $396,601.74 in Stock

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc acquired 31,033 shares of Zymeworks stock in a transaction that occurred on Friday, March 21st. The shares were purchased at an average price of $12.78 per share, for a total transaction of $396,601.74. Following the transaction, the director now directly owns 17,135,113 shares in the company, valued at $218,986,744.14. The trade was a 0.18 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, March 24th, Ecor1 Capital, Llc purchased 22,689 shares of Zymeworks stock. The shares were purchased at an average cost of $13.08 per share, for a total transaction of $296,772.12.
• On Wednesday, March 19th, Ecor1 Capital, Llc acquired 58,306 shares of Zymeworks stock. The stock was purchased at an average cost of $12.64 per share, with a total value of $736,987.84.
• On Monday, March 17th, Ecor1 Capital, Llc acquired 56,277 shares of Zymeworks stock. The stock was acquired at an average price of $12.23 per share, with a total value of $688,267.71.
• On Thursday, March 13th, Ecor1 Capital, Llc bought 468,356 shares of Zymeworks stock. The shares were acquired at an average cost of $12.48 per share, for a total transaction of $5,845,082.88.
• On Tuesday, March 11th, Ecor1 Capital, Llc purchased 320,690 shares of Zymeworks stock. The shares were acquired at an average cost of $11.49 per share, with a total value of $3,684,728.10.
• On Friday, January 17th, Ecor1 Capital, Llc acquired 19,748 shares of Zymeworks stock. The stock was acquired at an average cost of $13.87 per share, for a total transaction of $273,904.76.
• On Wednesday, January 15th, Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock. The shares were bought at an average cost of $14.01 per share, for a total transaction of $546,796.29.
• On Monday, January 13th, Ecor1 Capital, Llc purchased 74,125 shares of Zymeworks stock. The stock was bought at an average price of $13.39 per share, for a total transaction of $992,533.75.
• On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The shares were bought at an average price of $13.13 per share, with a total value of $2,679,806.74.
• On Wednesday, January 8th, Ecor1 Capital, Llc bought 21,021 shares of Zymeworks stock. The stock was bought at an average price of $14.07 per share, for a total transaction of $295,765.47.

Zymeworks Price Performance

Shares of ZYME traded up $0.33 during trading hours on Monday, hitting $13.05. The stock had a trading volume of 525,246 shares, compared to its average volume of 476,128. Zymeworks Inc. has a 1-year low of $7.97 and a 1-year high of $17.70. The firm has a market capitalization of $907.98 million, a P/E ratio of -8.70 and a beta of 1.13. The firm has a 50 day simple moving average of $13.71 and a 200-day simple moving average of $13.72.

Institutional Investors Weigh In On Zymeworks

Several hedge funds and other institutional investors have recently modified their holdings of ZYME. Polar Asset Management Partners Inc. acquired a new stake in Zymeworks in the 4th quarter valued at $527,000. Voloridge Investment Management LLC bought a new position in shares of Zymeworks in the fourth quarter valued at $640,000. Point72 Asset Management L.P. grew its holdings in shares of Zymeworks by 565.8% during the fourth quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company’s stock valued at $4,833,000 after buying an additional 280,544 shares during the last quarter. Nuveen Asset Management LLC increased its position in shares of Zymeworks by 0.4% during the fourth quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company’s stock worth $3,031,000 after acquiring an additional 886 shares in the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of Zymeworks by 1.2% in the 4th quarter. Deutsche Bank AG now owns 1,546,772 shares of the company’s stock worth $22,645,000 after acquiring an additional 17,849 shares during the last quarter. Institutional investors own 92.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ZYME shares. HC Wainwright boosted their price target on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Monday, March 10th. Lifesci Capital assumed coverage on shares of Zymeworks in a report on Tuesday, March 11th. They issued an “outperform” rating and a $30.00 target price on the stock. Citigroup increased their price target on Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, March 7th. JPMorgan Chase & Co. raised Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective on the stock in a research note on Monday, December 16th. Finally, Wells Fargo & Company raised their target price on Zymeworks from $12.00 to $14.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Zymeworks currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.